| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/06/2004 | US6759210 Compositions and methods for the treatment and diagnosis of cardiovascular disease using fehd545 as a target |
| 07/06/2004 | US6759201 Method of identifying a neural progenitor cell by evaluating expression of daedalos |
| 07/06/2004 | US6759194 Nucleotide sequences encoding peroxisome-associated polypeptides, and their uses in the diagnosis and/or treatment of lung injuries and diseases, and of oxidative stress-related disorders |
| 07/06/2004 | US6759188 Method for producing interleukin 1 receptor antagonists, a therapeutic activity protein, from body fluids |
| 07/06/2004 | US6759050 Stable; recombinant adeno-associated virus (raav) virions that provide protection against loss of transduceability due to manipulation, storage, transport; a dihydric or polyhydric alcohol; polyethylene glycol, propylene glycol, sorbitol |
| 07/06/2004 | US6759048 Neutralization-sensitive epitopes of Cryptosporidium parvum |
| 07/06/2004 | US6759047 Novel proteins arresten, canstatin and tumstatin; all comprise the c-terminal fragment of the nc1 (non-collagenous 1) domain of type iv collagenl; antitumor |
| 07/06/2004 | US6759046 Peptides |
| 07/06/2004 | US6759045 Administering antibodies; anticancer agents |
| 07/06/2004 | US6759043 Monoclonal antibodies having property of causing apoptosis |
| 07/06/2004 | US6759042 Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent |
| 07/06/2004 | US6759040 Mixtures for the prevention or treatment of dental caries, periodontal disease, cystic fibrosis, removal of biofilms from contact lenses, and diseases or complications associated with biofilm formation on implantable medical devices |
| 07/06/2004 | US6759037 Compositions and methods for treating diabetes |
| 07/06/2004 | US6759036 Fibrocyte-base vaccine formulations |
| 07/06/2004 | CA2433080C Stable enzymatic wound debrider |
| 07/06/2004 | CA2278759C Process for preparing synthetic soil-extract materials and medicaments based thereon |
| 07/06/2004 | CA2259163C Nt-3 and bdnf analogs having improved circulating life and/or absorption |
| 07/06/2004 | CA2153778C Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| 07/01/2004 | WO2004056080A1 Endothelial cell specifically binding peptides |
| 07/01/2004 | WO2004055514A1 Compounds and methods for detection of carcinomas and their precursor lesions |
| 07/01/2004 | WO2004055513A2 Use of cd137 antagonists for the treatment of tumors |
| 07/01/2004 | WO2004055201A2 Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| 07/01/2004 | WO2004055186A1 Guanosine triphosphate-binding protein-coupled receptor |
| 07/01/2004 | WO2004055184A1 GLUCOSE AND/OR FRUCTOSE TRANSPORTER NaGLT1 AND ITS GENE |
| 07/01/2004 | WO2004055158A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 07/01/2004 | WO2004055156A2 A vegf variant that lacks vegfr-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis |
| 07/01/2004 | WO2004055055A1 The transmembrane protein amigo and uses thereof |
| 07/01/2004 | WO2004055051A1 Transcription control factor zhx3 |
| 07/01/2004 | WO2004055049A1 Peptides impairing pbx dependent gene regulation |
| 07/01/2004 | WO2004055047A1 A novel phosphoprotein |
| 07/01/2004 | WO2004055046A2 Adam like genes of fungi |
| 07/01/2004 | WO2004055043A1 Epitopic peptides of the thyroperoxidase enzyme, compositions containing same and uses thereof |
| 07/01/2004 | WO2004055042A1 Biologically active peptide conjugates |
| 07/01/2004 | WO2004055041A2 Defensin-inducing peptides from fusobacterium |
| 07/01/2004 | WO2004055035A1 A group of nucleic acid fragments for prevention of hiv infection or aids and the usage thereof |
| 07/01/2004 | WO2004054614A1 Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom |
| 07/01/2004 | WO2004054609A1 Placental alkaline phosphatase to control diabetes |
| 07/01/2004 | WO2004054608A2 Lactoferrin in the reduction of pain |
| 07/01/2004 | WO2004054607A2 Stable therapeutic proteins |
| 07/01/2004 | WO2004054606A1 Method of decreasing hepatic glucose output in diabetic patients |
| 07/01/2004 | WO2004054605A1 Freeze-dried interferon-ϝ composition for transpulmonary administration and inhalation system therefor |
| 07/01/2004 | WO2004054604A1 Medicinal composition for treating ischemic cardiac failure |
| 07/01/2004 | WO2004054603A2 Use of beta-defensins for treating hiv infections |
| 07/01/2004 | WO2004054602A1 Orally administerable protein preparation and method of orally administering the same |
| 07/01/2004 | WO2004054594A1 Cell death inhibitor |
| 07/01/2004 | WO2004054586A1 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors |
| 07/01/2004 | WO2004054556A1 Pharmaceutical porous particles |
| 07/01/2004 | WO2004054555A1 Novel dry powder inhalation system for transpulmonary administration |
| 07/01/2004 | WO2004054516A2 Antagonists for human prolactin |
| 07/01/2004 | WO2004054510A2 Method for identifying modulators of human orexin-2 receptor |
| 07/01/2004 | WO2004054433A2 Forming iron nitrosyl hemoglobin |
| 07/01/2004 | WO2004048519A3 Treatment of mammalian reaction to ige interactions |
| 07/01/2004 | WO2004046170A3 Tubulysins, method for producing the same and tubulysin preparations |
| 07/01/2004 | WO2004044591A3 Use of nuclear hormone receptors to identify meiosis regulating compounds |
| 07/01/2004 | WO2004041859A3 Peptide fragments of the harp factor inhibiting angiogenesis |
| 07/01/2004 | WO2004040009A3 Protozoan rhomboid proteins |
| 07/01/2004 | WO2004033666A3 Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases |
| 07/01/2004 | WO2004029200A3 Method of enhancing proliferation and/or hematopoietic differentiation of stem cells |
| 07/01/2004 | WO2004029087A3 Bitter taste receptors |
| 07/01/2004 | WO2004028551A9 Novel agents that modulate eph receptor activity |
| 07/01/2004 | WO2004028474A3 Caspase inhibitors as anticancer agents |
| 07/01/2004 | WO2004024683A3 COMPOSITIONS FOR INDUCING INCREASED LEVELS OF β-CHEMOKINES AND METHODS OF USE THEREFOR |
| 07/01/2004 | WO2004020014A3 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 07/01/2004 | WO2004019884A3 Agents and methods for enhancing bone formation |
| 07/01/2004 | WO2004019865A3 Amelioration of effects of cigarette smoke |
| 07/01/2004 | WO2004018512A3 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications |
| 07/01/2004 | WO2004018498A3 Minicell display and products therefrom |
| 07/01/2004 | WO2004017921A3 Method for treating inflammatory bowel disease |
| 07/01/2004 | WO2004017044A8 Chimeric protein |
| 07/01/2004 | WO2004015126A3 Antisense modulation of edg1 expression |
| 07/01/2004 | WO2004011489A3 Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells |
| 07/01/2004 | WO2004010956A3 Antisense modulation of lar expression |
| 07/01/2004 | WO2004010894A3 Ophthalmologic irrigation solutions and method |
| 07/01/2004 | WO2004007540A8 Klebsiella membrane extracts exhibiting advantageous properties, and method for producing said extracts |
| 07/01/2004 | WO2004005513A3 Methods for specifically inhibiting histone deacetylase-7 and 8 |
| 07/01/2004 | WO2004005323A3 Affinity small molecules for the epo receptor |
| 07/01/2004 | WO2004000802A3 Scaffolded maleimide clusters for multivalent peptide assembly |
| 07/01/2004 | WO2004000222A3 The use of bacterial phage associated lysing proteins for treating bacterial dental caries |
| 07/01/2004 | WO2003106646A3 Antisense modulation of dual specific phosphatase 4 expression |
| 07/01/2004 | WO2003103608A3 Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| 07/01/2004 | WO2003102538A3 Combinatorial chemical library ii |
| 07/01/2004 | WO2003102015A3 Method and apparatus for detecting and monitoring peptides, and peptides identified therewith |
| 07/01/2004 | WO2003100435A3 Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2) |
| 07/01/2004 | WO2003097814A3 Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins |
| 07/01/2004 | WO2003096984A3 Drug therapy for celiac sprue |
| 07/01/2004 | WO2003092716A3 Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders |
| 07/01/2004 | WO2003092605A3 Protease inhibitors |
| 07/01/2004 | WO2003082217A3 Ctla4 compositions in the treatment of autism |
| 07/01/2004 | WO2003080569A3 Egfr ligands and methods of use |
| 07/01/2004 | WO2003074992A3 Phosphorylated proteins and uses related thereto |
| 07/01/2004 | WO2003068942A3 Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses |
| 07/01/2004 | WO2003057822A9 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 07/01/2004 | WO2003051278A3 Nanoparticle delivery vehicle |
| 07/01/2004 | WO2003048324A3 Antisense modulation of phospholipid scramblase 3 expression |
| 07/01/2004 | WO2003042240A3 Polypeptides of pseudomonas aeruginosa |
| 07/01/2004 | WO2003040366A3 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 07/01/2004 | WO2003029429A9 Traversal of nucleic acid molecules through a fluid space and expression in repair cells |
| 07/01/2004 | WO2003012045A3 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans |
| 07/01/2004 | WO2002077189A3 Glycosylation-resistant and nonglycosylated cyanovirins |
| 07/01/2004 | WO2002015846A3 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |